Temasek invested an undisclosed amount in Goa-based Molbio Diagnostics, which is known for its 'Truenat' technology which can be used for testing infectious diseases.

J. Sagar Associates advised Temasek on the deal.

The transaction team consisted of Vikram Raghani (Partner), Birbahadur Sachar (Partner), Yashvi Singh (Principal Associate) and Rishabh Sheth (Associate).

The competition team consisted of Vaibhav Choukse (Partner & Head of Practice, Competition Law), Ela Bali (Principal Associate), Aditi Khanna (Senior Associate) and Faiz Siddiqui (Associate).

Motilal Oswal Alternates is an existing investor in Molbio Diagnostics.

JSA had advised Motilal Oswal at the time of its investment as well.

Molbio Diagnostics' 'Truenat' portable technology is a battery-operated real-time PCR platform which enables early and accurate diagnosis of infectious diseases including TB, COVID-19, Hepatitis-C virus, human papillomavirus, influenza and vector-borne diseases like dengue, chikungunya and malaria. It also initiates correct treatment right at the first point of contact and can be deployed at all levels of the healthcare chain, including very remote and inaccessible areas.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.